James J. Java
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
James J. Java has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Krishnansu Sujata Tewari
University of California, Irvine, CA, United States of America
5 shared publications - David E. Cohn
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
3 shared publications - David Michael Mutch
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
3 shared publications - Joan L. Walker
Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City, OK
3 shared publications - Ritu Salani
Milan, Italy
3 shared publications - Roger B. Lee
Tacoma General Hospital, Tacoma, WA, United States of America
3 shared publications
Latest Publications
- 1 February 2019
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 133 (2) , 245-254
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
OBJECTIVE: To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian–peritoneal–tubal carcinoma and to develop a nomogram to predict individual survival after recurrence. METHODS: We retrospectively analyzed patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian–peritoneal–tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and subsequently developed recurrence. Prognostic factors affecting survival were identified and used to develop a nomogram, which was both internally and externally validated. RESULTS: There were 4,739 patients included in this analysis, of whom, 84% had stage III and 16% had stage IV ovarian carcinoma. At a median follow-up of 88.8 months (95% CI 86.2–92.0 months), the vast majority of patients (89.4%) had died. The median survival after recurrence was 21.4 months (95% CI 20.5–21.9 months). Time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age were significant variables used to develop a nomogram for survival after recurrence, which had a concordance index of 0.67. The time to recurrence alone accounted for 85% of the prognostic information. Similar results were found for patients who underwent second look laparotomy and had a complete pathologic response or received intraperitoneal chemotherapy. CONCLUSION: For individuals with advanced-stage ovarian carcinoma who recur after standard first-line therapy, estimated survivals after recurrence are closely related to the time to recurrence after chemotherapy and prognostic variables can be used to predict subsequent survival. CLINICAL TRIAL REGISTRATION: ClinialTrials.gov, NCT00002568, NCT00837993, NCT00002717, NCT01074398, and NCT00011986.
- 1 February 2019
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 133 (2) , 245-254
Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma
OBJECTIVE: To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian–peritoneal–tubal carcinoma and to develop a nomogram to predict individual survival after recurrence. METHODS: We retrospectively analyzed patients treated in multicenter Gynecologic Oncology Group protocols for stage III and IV ovarian–peritoneal–tubal carcinoma who underwent primary debulking surgery, received chemotherapy with paclitaxel and a platinum compound, and subsequently developed recurrence. Prognostic factors affecting survival were identified and used to develop a nomogram, which was both internally and externally validated. RESULTS: There were 4,739 patients included in this analysis, of whom, 84% had stage III and 16% had stage IV ovarian carcinoma. At a median follow-up of 88.8 months (95% CI 86.2–92.0 months), the vast majority of patients (89.4%) had died. The median survival after recurrence was 21.4 months (95% CI 20.5–21.9 months). Time to recurrence after initial chemotherapy, clear cell or mucinous histology, performance status, stage IV disease, and age were significant variables used to develop a nomogram for survival after recurrence, which had a concordance index of 0.67. The time to recurrence alone accounted for 85% of the prognostic information. Similar results were found for patients who underwent second look laparotomy and had a complete pathologic response or received intraperitoneal chemotherapy. CONCLUSION: For individuals with advanced-stage ovarian carcinoma who recur after standard first-line therapy, estimated survivals after recurrence are closely related to the time to recurrence after chemotherapy and prognostic variables can be used to predict subsequent survival. CLINICAL TRIAL REGISTRATION: ClinialTrials.gov, NCT00002568, NCT00837993, NCT00002717, NCT01074398, and NCT00011986.
- 1 January 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (1) , 49-55
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study
- 1 January 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 148 (1) , 49-55
Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study
- Open Access
- 1 May 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (4) , 730-737
Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients
- 1 May 2017
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 27 (4) , 730-737
Open AccessPathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients
- Open Access
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 484-489
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 484-489
Open AccessDoes time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study
- Open Access
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 460-465
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 460-465
Open AccessImpact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 490-495
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients – An analysis of NRG Oncology/Gynecologic Oncology Group trials
- 1 December 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (3) , 490-495
The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients – An analysis of NRG Oncology/Gynecologic Oncology Group trials
- Open Access
- 1 November 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (2) , 294-301
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
- 1 November 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 143 (2) , 294-301
Open AccessIs age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis
- 1 November 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 139 (2) , 221-227
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)
- 1 November 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 139 (2) , 221-227
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236)